Claude Gaillard

Gaillard in 1999 Claude Gaillard (born 15 August 1944 in Montriond) was a member of the National Assembly of France. He represents the Meurthe-et-Moselle department, and is a member of the Union for a Popular Movement. Provided by Wikipedia
Showing 1 - 10 results of 10 for search 'Claude Gaillard', query time: 0.04s Refine Results
  1. 1
    Heritabilities for the puppy weight at birth in Labrador retrievers

    Heritabilities for the puppy weight at birth in Labrador retrievers by Claude Schelling, Claude Gaillard, Jane Russenberger, Lou Moseley, Gaudenz Dolf

    Published 2019-11-01
    Get full text
    Article
  2. 2
    Factors contributing to the decision to perform a cesarean section in Labrador retrievers

    Factors contributing to the decision to perform a cesarean section in Labrador retrievers by Gaudenz Dolf, Claude Gaillard, Jane Russenberger, Lou Moseley, Claude Schelling

    Published 2018-02-01
    Get full text
    Article
  3. 3
    Zero Echo Time <sup>17</sup>O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis

    Zero Echo Time <sup>17</sup>O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis by Celine Baligand, Olivier Barret, Amélie Tourais, Jean-Baptiste Pérot, Didier Thenadey, Fanny Petit, Géraldine Liot, Marie-Claude Gaillard, Julien Flament, Marc Dhenain, Julien Valette

    Published 2021-04-01
    Get full text
    Article
  4. 4
    Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing

    Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing by Karine Cambon, Virginie Zimmer, Sylvain Martineau, Marie-Claude Gaillard, Margot Jarrige, Aurore Bugi, Jana Miniarikova, Maria Rey, Raymonde Hassig, Noelle Dufour, Gwenaelle Auregan, Philippe Hantraye, Anselme L. Perrier, Nicole Déglon

    Published 2017-06-01
    Get full text
    Article
  5. 5
    IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.

    IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. by Romina Aron Badin, Brigitte Spinnewyn, Marie-Claude Gaillard, Caroline Jan, Carole Malgorn, Nadja Van Camp, Frédéric Dollé, Martine Guillermier, Sabrina Boulet, Anne Bertrand, Marc Savasta, Michel Auguet, Emmanuel Brouillet, Pierre-Etienne Chabrier, Philippe Hantraye

    Published 2013-01-01
    Get full text
    Article
  6. 6
    Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates.

    Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates. by Romina Aron Badin, Brigitte Spinnewyn, Marie-Claude Gaillard, Caroline Jan, Carole Malgorn, Nadja Van Camp, Frédéric Dollé, Martine Guillermier, Sabrina Boulet, Anne Bertrand, Marc Savasta, Michel Auguet, Emmanuel Brouillet, Pierre-Etienne Chabrier, Philippe Hantraye

    Published 2013-01-01
    Get full text
    Article
  7. 7
    THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency

    THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency by Audrey Vautheny, Charlotte Duwat, Gwennaëlle Aurégan, Charlène Joséphine, Anne-Sophie Hérard, Caroline Jan, Julien Mitja, Pauline Gipchtein, Marie-Claude Gaillard, Luc Buée, David Blum, Philippe Hantraye, Gilles Bonvento, Emmanuel Brouillet, Karine Cambon, Alexis-Pierre Bemelmans

    Published 2021-07-01
    Get full text
    Article
  8. 8
    Development of an AAV-based model of tauopathy targeting retinal ganglion cells and the mouse visual pathway to study the role of microglia in Tau pathology

    Development of an AAV-based model of tauopathy targeting retinal ganglion cells and the mouse visual pathway to study the role of microglia in Tau pathology by Charlotte Duwat, Pauline Léal, Audrey Vautheny, Gwennaëlle Aurégan, Charlène Joséphine, Marie-Claude Gaillard, Anne-Sophie Hérard, Caroline Jan, Pauline Gipchtein, Julien Mitja, Stéphane Fouquet, Marie-Laure Niepon, Philippe Hantraye, Emmanuel Brouillet, Gilles Bonvento, Karine Cambon, Alexis-Pierre Bemelmans

    Published 2023-06-01
    Get full text
    Article
  9. 9
    The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo

    The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo by Noémie Cresto, Marie-Claude Gaillard, Camille Gardier, Francesco Gubinelli, Elsa Diguet, Déborah Bellet, Laurine Legroux, Julien Mitja, Gwenaëlle Auregan, Martine Guillermier, Charlène Josephine, Caroline Jan, Noëlle Dufour, Alain Joliot, Philippe Hantraye, Gilles Bonvento, Nicole Déglon, Alexis-Pierre Bemelmans, Karine Cambon, Géraldine Liot, Emmanuel Brouillet

    Published 2020-02-01
    Get full text
    Article
  10. 10
    The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo

    The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo by Noémie Cresto, Camille Gardier, Marie-Claude Gaillard, Francesco Gubinelli, Pauline Roost, Daniela Molina, Charlène Josephine, Noëlle Dufour, Gwenaëlle Auregan, Martine Guillermier, Suéva Bernier, Caroline Jan, Pauline Gipchtein, Philippe Hantraye, Marie-Christine Chartier-Harlin, Gilles Bonvento, Nadja Van Camp, Jean-Marc Taymans, Karine Cambon, Géraldine Liot, Alexis-Pierre Bemelmans, Emmanuel Brouillet

    Published 2021-06-01
    Get full text
    Article

Search Tools: